Arcus Biosciences Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Arcus Biosciences Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 19 Feb 2021 | Lorem |
| Arcus’ Phase Ib/II etrumadenant has intriguing mechanism for 1L pancreatic cancer but kinks need to be ironed out to solidify potential; superiority over SOCs desired for long-term success, experts say | 19 Feb 2021 | Reynald Castaneda |
| Easing adenosine effect in solid tumours leaves experts dubious despite the rationale to help an immune response; combination approach could improve efficacy potential, experts say | 14 Sep 2018 | Reynald Castaneda,Manasi Vaidya |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer